Thank you @AhmadSherbini for discussing his #ACR21 research on @RheumNow on Abs#1444 - Can we predict which patients are most likely to have nausea or alopecia intolerance to MTX? https://t.co/I5WmCECq7v

Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws

• Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis - ACR …

Methotrexate did not improve Ustekinumab efficacy in tx of PsA ⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function #ACR21 #ACRBest @RheumNow Abs#L12 https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV

• https://bit.ly/3wvtoDl

No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06

GLORIA study of adding prednisolone 5mg to DMARDs over 2 years for RA in those >65 years. Mean DAS 0.37 points lower, Sharp score 1.7 lower (are either of these clinically significant?). NNH 9.5. To me causing harm chasing statistical benefit Abstr#1678 #ACR21 @RheumNow #ACRBest https://t.co/KYk1II3J3w

Dr Hebing on s/c vs oral methotrexate. erythrocyte methotrexate polyglutamates significantly higher with s/c administration. s/c consistently seems to be the better option, better efficacy, less side effects. Abstr#1695 #ACR21 @RheumNow https://t.co/kLGr6pVnxQ

No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i ⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD ⭐️no specific clustering noted Abs#1782 #ACR21 @RheumNow https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo

• https://bit.ly/3D3tO6b

#ACR21 Abs#1677. Effects of bDMARD on Lipids: ⬆️ HDL from 62 -> 66 in 1yr (p=0.013) ❌ No signif change in LDL or LDL-C/HDL-C ratios @Rheumnow https://t.co/uMsXKwwqvW https://t.co/fhCbDoa3px

• https://bit.ly/3bSS27l

SELECT-EARLY results for #upadacitinib in #RA 👉🏼UPA better than MTX for clinical response and remission 👉🏼⬆️rates of HZ, neutropenia, CPK elevations 👉🏼No new safety risks identified Abs#1692 #ACR21 @RheumNow https://t.co/wJy7MK4pyF https://t.co/YNpE1Axiw0

• Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthr…